Boehringer Ingelheim and Zealand Pharma's obesity drug, Survodutide, shows no increased heart risk and significant weight loss in a late-stage trial, paving the way for global regulatory approval.
Divi's Laboratories announces the establishment of new Solid Phase Peptide Synthesis (SPPS) lines to cater to increasing ...
Eli Lilly's Phase 3 trial reveals that its weight-loss pill Foundayo effectively reduces obstructive sleep apnea severity, ...
The US FDA has mandated new warnings for GLP-1 medications, including Ozempic and Zepbound, regarding a potential eye ...
AstraZeneca strengthens its vaccine pipeline by acquiring early-stage biotech firm Omniose, which specializes in developing ...
Mumbai: Drugmaker Lupin Limited ha launched raltegravir tablets in the US, following the approval of its Abbreviated New Drug ...
Zura Bio announces the failure of its experimental drug tibulizumab in a mid-stage trial for treating hidradenitis ...
BDR Pharmaceuticals has acquired a controlling stake in Acme Formulations' oral solid formulations division, enhancing its ...
India's NPPA caps trade margins on anti-cancer drugs to reduce costs significantly, aiming for annual savings of ₹2,500 crore ...
Alembic Pharmaceuticals has received final approval from the US FDA for its Olopatadine Hydrochloride ophthalmic solution, a ...
The FDA has approved Bayer's new blood thinner Sunharbo to prevent recurrent strokes in patients. This innovative treatment ...
Morepen Laboratories launches desloratadine, a second-generation antihistamine for allergies, entering the US pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results